{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:21:27Z","timestamp":1789683687818,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Bone metastases constitute a\u00a0common indication for both conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT). Although in recent years guidelines have been proposed for SBRT of spinal and non-spinal metastases, little is known about the use of bone SBRT and the actual patterns of care in German-speaking countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>We performed an online survey among radiation oncologists (ROs) registered with the interdisciplinary Radiosurgery and Stereotactic Radiotherapy Working Group of the German Society of Radiation Oncology (DEGRO) and the German Society for Medical Physics (DGMP) to collect valuable and robust cross-sectional data on patterns of care for bone SBRT in German-speaking countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the registered ROs, 35.5% (75\/211) completed the online survey. ROs working in high-volume centers irradiating more than 100 patients with bone metastases annually represented the largest group, with 58.7%. Ablative SBRT was mostly performed for bone oligometastases (78.7%). For symptom-directed palliative radiotherapy, the majority of responding physicians (84.3%) still mostly recommend moderately hypofractionated treatment. Nevertheless, 60.9% of participating ROs stated using bone SBRT at least occasionally, also for palliative purposes such as pain control. Our survey also revealed a\u00a0certain reluctance for the concomitant use of systemic therapies with bone SBRT and heterogeneity regarding target volume definition and dosing for bone SBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our survey demonstrates that bone SBRT for spinal and non-spinal metastases for oligometastatic disease (OMD) is broadly available in clinical routine care in German-speaking countries. A\u00a0large heterogeneity regarding indications, dose, and fractionation concepts remains, requiring further efforts for standardization of bone SBRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-025-02387-y","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:14:06Z","timestamp":1742296446000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic radiotherapy for spinal and non-spinal bone metastases: a\u00a0patterns-of-care analysis in German-speaking countries as part of a\u00a0project of the interdisciplinary Radiosurgery and Stereotactic Radiotherapy Working Group of the DEGRO\/DGMP"],"prefix":"10.1007","volume":"202","author":[{"given":"F.","family":"N\u00e4gler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gleim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Moustakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. B.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wittig-Sauerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"8","key":"2387_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy\u00a0GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593. https:\/\/doi.org\/10.1038\/nrc867","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2387_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman\u00a0RE, Croucher\u00a0PI, Padhani\u00a0AR et\u00a0al (2020) Bone metastases. Nat Rev Dis Primers 6(1):83. https:\/\/doi.org\/10.1038\/s41572-020-00216-3","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2387_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.radonc.2015.10.015","volume":"118","author":"MS Tiwana","year":"2016","unstructured":"Tiwana\u00a0MS, Barnes\u00a0M, Yurkowski\u00a0E et\u00a0al (2016) Incidence and treatment patterns of complicated bone metastases in a\u00a0population-based radiotherapy program. Radiother Oncol 118(3):552\u2013556. https:\/\/doi.org\/10.1016\/j.radonc.2015.10.015","journal-title":"Radiother Oncol"},{"key":"2387_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden\u00a0J, Willmann\u00a0J, Spa\u0142ek\u00a0M et\u00a0al (2022) ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol 173:197\u2013206. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.024","journal-title":"Radiother Oncol"},{"issue":"1","key":"2387_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz\u00a0S, Balboni\u00a0T, Jones\u00a0J et\u00a0al (2017) Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 7(1):4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"2387_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","volume":"24","author":"E Chow","year":"2012","unstructured":"Chow\u00a0E, Zeng\u00a0L, Salvo\u00a0N et\u00a0al (2012) Update on the Systematic Review of Palliative Radiotherapy Trials for Bone Metastases. Clin Oncol 24(2):112\u2013124. https:\/\/doi.org\/10.1016\/j.clon.2011.11.004","journal-title":"Clin Oncol"},{"issue":"1","key":"2387_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman\u00a0S, Weichselbaum\u00a0RR (1995) Oligometastases. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2387_CR8","doi-asserted-by":"publisher","first-page":"30718","DOI":"10.1016\/s1470-2045","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M, Lievens\u00a0Y, Bouma\u00a0AB et\u00a0al (2020) Characterisation and classification of oligometastatic disease: a\u00a0European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet 21(1):30718\u201330711. https:\/\/doi.org\/10.1016\/s1470-2045","journal-title":"Lancet"},{"issue":"5","key":"2387_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","volume":"196","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M, Baus\u00a0WW, Blanck\u00a0O et\u00a0al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 196(5):417\u2013420. https:\/\/doi.org\/10.1007\/s00066-020-01603-1","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"2387_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00066-024-02254-2","volume":"200","author":"TB Brunner","year":"2024","unstructured":"Brunner\u00a0TB, Boda-Heggemann\u00a0J, B\u00fcrgy\u00a0D et\u00a0al (2024) Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 200(9):737\u2013750. https:\/\/doi.org\/10.1007\/s00066-024-02254-2","journal-title":"Strahlenther Onkol"},{"issue":"25","key":"2387_CR11","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S et\u00a0al (2020) Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase\u00a0II Randomized Trial. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10185","key":"2387_CR12","doi-asserted-by":"publisher","first-page":"32487","DOI":"10.1016\/S0140-6736","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S et\u00a0al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a\u00a0randomised, phase\u00a02, open-label trial. Lancet 393(10185):32487\u201332485. https:\/\/doi.org\/10.1016\/S0140-6736","journal-title":"Lancet"},{"issue":"4","key":"2387_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow\u00a0S, Palma\u00a0DA, Olson\u00a0R et\u00a0al (2022) Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol 114(4):611\u2013616. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004","journal-title":"Int J Radiat Oncol"},{"issue":"16","key":"2387_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura\u00a0SJ, Winter\u00a0KA, Woodward\u00a0WA et\u00a0al (2022) NRG-BR002: A\u00a0phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). JCO 40(16):1007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1007","journal-title":"JCO"},{"issue":"16","key":"2387_CR15","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar\u00a0P, Hu\u00a0C, Gomez\u00a0DR et\u00a0al (2024) NRG-LU002: Randomized phase\u00a0II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). JCO 42(16):8506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8506","journal-title":"JCO"},{"issue":"10422","key":"2387_CR16","doi-asserted-by":"publisher","first-page":"01857","DOI":"10.1016\/S0140-6736","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai\u00a0CJ, Yang\u00a0JT, Shaverdian\u00a0N et\u00a0al (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block CURB oligoprogression): an open-label, randomised, controlled, phase\u00a02\u00a0study. Lancet 403(10422):1857\u20131853. https:\/\/doi.org\/10.1016\/S0140-6736 (London, England)","journal-title":"Lancet"},{"issue":"4","key":"2387_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11912-024-01515-8","volume":"26","author":"AJ Grosinger","year":"2024","unstructured":"Grosinger\u00a0AJ, Alcorn\u00a0SR (2024) An Update on the Management of Bone Metastases. Curr Oncol Rep 26(4):400\u2013408. https:\/\/doi.org\/10.1007\/s11912-024-01515-8","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"2387_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijrobp.2020.07.2253","volume":"108","author":"T Nguyen","year":"2020","unstructured":"Nguyen\u00a0T, Chin\u00a0L, Sahgal\u00a0A et\u00a0al (2020) International Consensus Contouring Recommendations for Stereotactic Body Radiotherapy of Non-Spine Bone Metastases. Int J Radiat Oncol 108(3):90. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.2253","journal-title":"Int J Radiat Oncol"},{"issue":"6","key":"2387_CR19","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/j.prro.2020.02.011","volume":"10","author":"TK Nguyen","year":"2020","unstructured":"Nguyen\u00a0TK, Sahgal\u00a0A, Dagan\u00a0R et\u00a0al (2020) Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Pract Radiat Oncol 10(6):e452\u2013e460. https:\/\/doi.org\/10.1016\/j.prro.2020.02.011","journal-title":"Pract Radiat Oncol"},{"key":"2387_CR20","doi-asserted-by":"publisher","first-page":"109966","DOI":"10.1016\/j.radonc.2023.109966","volume":"190","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger\u00a0M, Andratschke\u00a0N, Belka\u00a0C et\u00a0al (2024) ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases. Radiother Oncol J Eur Soc Ther Radiol Oncol 190:109966. https:\/\/doi.org\/10.1016\/j.radonc.2023.109966","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2387_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2019.11.026","volume":"145","author":"EM Dunne","year":"2020","unstructured":"Dunne\u00a0EM, Sahgal\u00a0A, Lo\u00a0SS et\u00a0al (2020) International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol J Eur Soc Ther Radiol Oncol 145:21\u201329. https:\/\/doi.org\/10.1016\/j.radonc.2019.11.026","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2387_CR22","doi-asserted-by":"publisher","first-page":"100716","DOI":"10.1016\/j.ctro.2023.100716","volume":"45","author":"L Burgess","year":"2024","unstructured":"Burgess\u00a0L, Nguyen\u00a0E, Tseng\u00a0C\u2011L et\u00a0al (2024) Practice and principles of stereotactic body radiation therapy for spine and non-spine bone metastases. Clin Transl Radiat Oncol 45:100716. https:\/\/doi.org\/10.1016\/j.ctro.2023.100716","journal-title":"Clin Transl Radiat Oncol"},{"key":"2387_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ctro.2022.08.006","volume":"37","author":"F Vilotte","year":"2022","unstructured":"Vilotte\u00a0F, Pasquier\u00a0D, Blanchard\u00a0P et\u00a0al (2022) Stereotactic body radiation therapy for spine and non-spine bone metastases. GETUG (french society of urological radiation oncologists) recommendations using a\u00a0national two-round modified Delphi survey. Clin Transl Radiat Oncol 37:33\u201340. https:\/\/doi.org\/10.1016\/j.ctro.2022.08.006","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2387_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00066-023-02082-w","volume":"200","author":"M Waltenberger","year":"2024","unstructured":"Waltenberger\u00a0M, Vogel\u00a0MME, Bernhardt\u00a0D et\u00a0al (2024) Radiotherapy concepts for spinal metastases-results from an online survey among radiation oncologists of the German Society for Radiation Oncology. Strahlentherapie Onkol Organ Dtsch Rontgengesellschaft 200(2):159\u2013174. https:\/\/doi.org\/10.1007\/s00066-023-02082-w","journal-title":"Strahlentherapie Onkol Organ Dtsch Rontgengesellschaft"},{"key":"2387_CR25","unstructured":"R Core Team (2023) R: A\u00a0Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/"},{"key":"2387_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","volume":"173","author":"E Oldenburger","year":"2022","unstructured":"Oldenburger\u00a0E, Brown\u00a0S, Willmann\u00a0J et\u00a0al (2022) ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol J Eur Soc Ther Radiol Oncol 173:240\u2013253. https:\/\/doi.org\/10.1016\/j.radonc.2022.06.002","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"2","key":"2387_CR27","doi-asserted-by":"publisher","first-page":"e2355409","DOI":"10.1001\/jamanetworkopen.2023.55409","volume":"7","author":"BJJ Bindels","year":"2024","unstructured":"Bindels\u00a0BJJ, Mercier\u00a0C, Gal\u00a0R et\u00a0al (2024) Stereotactic Body and Conventional Radiotherapy for Painful Bone Metastases: A\u00a0Systematic Review and Meta-Analysis. Jama Netw Open 7(2):e2355409. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.55409","journal-title":"Jama Netw Open"},{"issue":"1","key":"2387_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijrobp.2019.06.382","volume":"105","author":"S Ryu","year":"2019","unstructured":"Ryu\u00a0S, Deshmukh\u00a0S, Timmerman\u00a0RD et\u00a0al (2019) Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase\u00a0III Results of NRG Oncology\/RTOG 0631. Int J Radiat Oncol 105(1):2\u2013S3. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.382","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"2387_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","volume":"128","author":"T Sprave","year":"2018","unstructured":"Sprave\u00a0T, Verma\u00a0V, F\u00f6rster\u00a0R et\u00a0al (2018) Randomized phase\u00a0II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 128(2):274\u2013282. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.030","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"6","key":"2387_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","volume":"5","author":"Q-N Nguyen","year":"2019","unstructured":"Nguyen\u00a0Q\u2011N, Chun\u00a0SG, Chow\u00a0E et\u00a0al (2019) Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A\u00a0Randomized Phase\u00a02 Trial. JAMA Oncol 5(6):872\u2013878. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0192","journal-title":"JAMA Oncol"},{"issue":"2","key":"2387_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijrobp.2020.11.060","volume":"110","author":"BJ Pielkenrood","year":"2021","unstructured":"Pielkenrood\u00a0BJ, van der Velden\u00a0JM, van der Linden\u00a0YM et\u00a0al (2021) Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases\u2014A Phase\u00a02 Randomized Controlled Trial Within a\u00a0Prospective Cohort. Int J Radiat Oncol Biol Phys 110(2):358\u2013367. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.060","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"2387_CR32","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/cncr.35310","volume":"130","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger\u00a0M, Billiet\u00a0C, Schnell\u00a0D et\u00a0al (2024) Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A\u00a0randomized phase\u00a03\u00a0trial. Cancer 130(15):2713\u20132722. https:\/\/doi.org\/10.1002\/cncr.35310","journal-title":"Cancer"},{"issue":"7","key":"2387_CR33","doi-asserted-by":"publisher","first-page":"00196","DOI":"10.1016\/S1470-2045","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal\u00a0A, Myrehaug\u00a0SD, Siva\u00a0S et\u00a0al (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicenter, randomised, controlled, phase\u00a02\/3\u00a0trial. Lancet Oncol 22(7):196\u2013190. https:\/\/doi.org\/10.1016\/S1470-2045","journal-title":"Lancet Oncol"},{"issue":"5","key":"2387_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.prro.2024.04.018","volume":"14","author":"S Alcorn","year":"2024","unstructured":"Alcorn\u00a0S, Cort\u00e9s \u00c1A, Bradfield\u00a0L et\u00a0al (2024) External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 14(5):377\u2013397. https:\/\/doi.org\/10.1016\/j.prro.2024.04.018","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2387_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","volume":"42","author":"EF Gillespie","year":"2024","unstructured":"Gillespie\u00a0EF, Yang\u00a0JC, Mathis\u00a0NJ et\u00a0al (2024) Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A\u00a0Multicenter, Randomized Phase\u00a0II Clinical Trial. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 42(1):38\u201346. https:\/\/doi.org\/10.1200\/JCO.23.00753","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"2387_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00066-023-02195-2","volume":"200","author":"M Guhlich","year":"2024","unstructured":"Guhlich\u00a0M, Rieken\u00a0S (2024) Prophylaktische Strahlentherapie bei asymptomatischen Hochrisiko-Knochenmetastasen. Strahlenther Onkol 200(3):253\u2013254. https:\/\/doi.org\/10.1007\/s00066-023-02195-2 (Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases)","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"2387_CR37","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1200\/JCO.23.02391","volume":"42","author":"AW Chan","year":"2024","unstructured":"Chan\u00a0AW, Simone\u00a0CB, van der Linden\u00a0Y et\u00a0al (2024) Prophylactic Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A\u00a0New Standard of Care or Need for More Data? J\u00a0Clin Oncol Off J Am Soc Clin Oncol 42(11):1326\u20131327. https:\/\/doi.org\/10.1200\/JCO.23.02391","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2387_CR38","doi-asserted-by":"publisher","first-page":"109969","DOI":"10.1016\/j.radonc.2023.109969","volume":"190","author":"RS Guninski","year":"2024","unstructured":"Guninski\u00a0RS, Cuccia\u00a0F, Alongi\u00a0F et\u00a0al (2024) Efficacy and safety of SBRT for spine metastases: A\u00a0systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol J Eur Soc Ther Radiol Oncol 190:109969. https:\/\/doi.org\/10.1016\/j.radonc.2023.109969","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2387_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194780","author":"SGC Kroeze","year":"2021","unstructured":"Kroeze\u00a0SGC, Fritz\u00a0C, Schaule\u00a0J et\u00a0al (2021) Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A\u00a0Retrospective Multi-Center Safety and Efficacy Analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers13194780","journal-title":"Cancers"},{"issue":"3","key":"2387_CR40","doi-asserted-by":"publisher","first-page":"00752","DOI":"10.1016\/s1470-2045","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze\u00a0SGC, Pavic\u00a0M, Stellamans\u00a0K et\u00a0al (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet 24(3):752\u2013755. https:\/\/doi.org\/10.1016\/s1470-2045","journal-title":"Lancet"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02387-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:18:42Z","timestamp":1768915122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02387-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2387"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02387-y","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.\u00a0Krug has received honoraria from Astra Zeneca, best practice onkologie, ESO, ESMO, Gilead, med update, Merck Sharp & Dohme, Novartis, Onkowissen, and Pfizer, as well as research funding from Stiftung Deutsche Krebshilfe and Merck KGaA. F.\u00a0N\u00e4gler, N.\u00a0Gleim, I.\u00a0Seiler, A.\u00a0R\u00fchle, K.\u00a0Hering, C.\u00a0Seidel, E.\u00a0Gkika, O.\u00a0Blanck, C.\u00a0Moustakis, T.\u00a0B.\u00a0Brunner, A.\u00a0Wittig-Sauerwein, and N.\u00a0H.\u00a0Nicolay declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}